Health & Environmental Research Online (HERO)


Print Feedback Export to File
7347398 
Journal Article 
Review 
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19 
Formiga, FR; Leblanc, R; de Souza Rebouças, J; Farias, LP; de Oliveira, RN; Pena, L 
2021 
Yes 
Journal of Controlled Release
ISSN: 0168-3659
EISSN: 1873-4995 
329 
758-761 
English 
33038449 
Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.